A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial-Reference-Cited by-同舟云学术

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Published:2015-12 Issue:1 Volume:5 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Ichinohe Tatsuo,Kuroda Yoshiaki,Okamoto Shinichiro,Matsue Kosei,Iida Shinsuke,Sunami Kazutaka,Komeno Takuya,Suzuki Kenshi,Ando Kiyoshi,Taniwaki Masafumi,Tobinai Kensei,Chou Takaaki,Kaneko Hitomi,Iwasaki Hiromi,Uemura Chie,Tamakoshi Hiromi,Zaki Mohamed H.,Doerr Thomas,Hagiwara Shotaro

Funder

Celgene K.K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s40164-016-0040-7

Reference37 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

2. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26:149–57 (Erratum in: Leukemia. 2012;26(5):1153).

3. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24:22–32.